Out-of-Specification Sample-Size Confusion - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Out-of-Specification Sample-Size Confusion
Precedents set in the historic Barr case continue to raise questions over suitable sample-size criteria.

Pharmaceutical Technology
pp. 28, 54

Statistical formula with historical estimates

As I tell my clients, the statistical answer to the sample-size question is: "We first need a prior estimate of the inherent variability, the variance under exactly the same conditions to be used, an estimate of the alpha risk level, the beta risk level, and the size of the difference to be detected."

The formula for the sample size for a difference from a mean is:

where t α and t β are the one sided t distribution values for the given α and β risk levels selected and S 2 is the variance of the total product, process or method and d is the difference to be detected.

Four values are needed to calculate the sample size. The alpha and beta errors are standardized for most scientific and industrial applications to α = 0.05, β = 0.05 or 0.10. Thus, the t values are taken from the standard t table for α and β and a given number of degrees of freedom of the data used to estimate the variance. The other two values are more difficult to obtain.

According to FDA, "The number may vary depending upon the variability of the particular test ..." (2). This prior estimate of the variance of the method for a given product may be difficult to obtain. If the product, process or method has been changed, the data must be limited to that last change to be representative. Also, some products are made only a few times a year. There may be only three or four batches and thus three or four values. This amount is not enough to get a good estimate of the variance. If sufficient data does exist, from historical records, then perhaps the estimate can be made. A sample size of 30 or more is preferred to obtain a reasonable estimate of the standard deviation.

The size of the difference to be detected is difficult to determine in advance because one does not know in advance how far out of specification any future OOS result may be.

If the specification is 95% and the OOS is 89%, then the difference to be detected is 6%. But if the OOS is 94.4%, the difference to be detected is 0.6%. These would give very different sample sizes.

Thus, there seems to be an inherent and unintended conflict within the industry on sample size. One is not allowed to adjust the number of retests depending on the results obtained, but that is the very information we need to statistically and scientifically determine the sample size.

To determine the sample size in advance without knowing how far out of specification the OOS result will be, one would need to decide on a difference to detect in advance. But how to select this difference? Should it be the best guess of the analysts? How does one justify that guess? Should it be the bias in the method from the validation, if it exists? If the bias is large, the sample size would be small. If the bias is very small, the sample size will be large, as can be seen from the equation. This seems to be the opposite of what industry wants to achieve.

Statistical formula with sample

Equation 1 can also be used if a first sample size (e.g., seven) is available to estimate the variance. With this variance estimate and the difference between the specification and the OOS result, the sample size needed can be recalculated. Additional samples would be taken to meet the sample size if greater than seven.

Equation 1 assumes a continuous response that is normally distributed. Some data, such as for a limulus amebocyte lysate test, may be skewed, and colony counts are both discrete and skewed, so a different model and formula must be used to get the estimate. There are books and computer programs dedicated to determining the sample size in different situations.

Further, from a laboratory management point of view, should a different number of OOS retests be pursued for each method? Do the statistical and scientific advantages of different sample sizes outweigh the need for consistency for the analysts to prevent confusion and mistakes? Are we out of compliance if the analyst does eight retests when the method calls for seven?


To conclude, there seems to be an inherent conflict in the industry's position on sample size. Given this discussion, the seven out of eight criteria given in the Barr case may be as good as any.

Lynn D. Torbeck is a statistician at PharmStat Consulting, 2000 Dempster, Evanston, IL 60202, tel. 847.424.1314,
, http://www.PharmStat.com/.


1. United States vs. Barr Laboratories, Inc. Civil Action No. 92-1744, US District Court for the District of New Jersey: 812 F. Supp. 458. 1993 US Dist. Lexis 1932; 4 Feb. 1993, as amended 30 Mar. 1993.

2. FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, Oct. 2006).

The author would like to extend an open-ended invitation to those interested in this issue to send their comments and solutions to
. Given adequate response, the information will be shared in a future column.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here